Phase II Study of UFT in Patients With Advanced Non-Small Cell Lung Cancer

1 June 1986

journal article
research article
Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology

Vol. 16 (2) , 143-146
https://doi.org/10.1093/oxfordjournals.jjco.a039130

Abstract

A phase II study of UFT (a mixture of uracil and tegafur; molar ratio of uracil to tegafur = 4) was undertaken in 21 patients with advanced non-small cell lung cancer (NSCLC). UFT was administered orally at a dose of 400 mg/m² every day, for more than four weeks. Of 16 adequately treated patients, one (6.3%) showed a partial response. Toxic effects included minimal myelosuppression, anorexia, nausea, vomiting and epigastralgia. Gastrointestinal toxicity was well tolerated. Considering the poor response and mild toxicity, a further phase II study of higher-dose UFT is necessary for patients without prior therapy.

Keywords

PHASE 2 CLINICAL TRIALS
TOXIC EFFECT
LOSS OF APPETITE
TEGAFUR/URACIL
GASTROINTESTINAL TOXICITY
PARTIAL RESPONSE
URACIL
MOLAR TOOTH
MYELOSUPPRESSION
NAUSEA AND VOMITING
ANOREXIA NERVOSA
EPIGASTRIC PAIN

This publication has 0 references indexed in Scilit: